Compare Quantumscape Corp (QS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Zimmer Biomet Holdings Inc — how do they compare? Quantumscape Corp trades at $4.6 (market cap $2.82B), while Zimmer Biomet Holdings Inc trades at $89.81 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6× Quantumscape Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quantumscape Corp for 37 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| QS | ZBH | |
|---|---|---|
Market Cap | $2.82B | $16.95B |
Volume | 21,878,246 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $103.98 |
52-Week Low | $4.52 | $79.58 |
Typical Hold Time | 37 Days | 89 Days |
Enterprise Value | $2.03B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.52, down 2.8% on the day, reflecting ongoing investor skepticism about the solid-state battery developer's path to commercialization. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamental challenges persist with zero revenue, negative EBITDA of -$358.25M (2025), and consecutive quarterly losses. Recent news highlights commercialization delays and insider selling, though the company continues ramping pilot production lines for automotive and new market applications.
The outlook remains high-risk with commercialization not expected until 2029, creating significant execution and competitive threats. While the consensus price target of $10.35 suggests potential upside from current levels, analyst sentiment is cautious with 73% hold ratings. Investment opportunity exists only for speculative investors comfortable with pre-revenue developmental stage risks and extended timelines to profitability.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
